Clinical trial

Male patient with doctor
#Archeus Technologies #Clinical trial #Prostate cancer #Radiopharmaceuticals

First patient dosed in Phase I trial of prostate cancer drug 

The first patient has been dosed in the Phase I clinical trial of ART-101 in men with metastatic castration-resistant prostate cancer (mCRPC).  ART-101 is a novel receptor-based targeting small molecule developed for the imaging and treatment of prostate cancer. The therapy targets prostate-specific membrane antigen (PSMA) and,… Read More

#Cancer Research #News

#AL Amyloidosis #Clinical trial #Financing

Protego raises $130 million to advance AL amyloidosis treatment 

Biotechnology company Protego Biopharma has raised $130 million to advance its first-in-class AL amyloidosis programme to clinical trial.  The proceeds from the over-subscribed Series B financing round will advance Protego’s lead candidate, PROT-001, into a pivotal clinical trial for AL amyloidosis. PROT-001 works by stabilising immunoglobulin light chains and preventing amyloid buildup, addressing disease at its root cause… Read More

#Business & Investment #News

Subcutaneous injection
#ABPI #Clinical trial #UK #UK government

Decline in trial recruitment denying patients, ABPI warns 

The decline in commercial clinical trial recruitment is denying patients participation in cutting-edge research, the Association of the British Pharmaceutical Industry (ABPI) has warned.  According to the ABPI’s annual clinical trials report, the number of patients recruited into UK industry clinical trials fell by 25% between 2022/23… Read More

#News

Scientist in laboratory
#Biotechnology #Cancer research #Clinical trial

First patient dosed in trial of MTHFD1/2 inhibitor  

The first patient has been dosed in the Phase I/II clinical trial of a MTHFD1/2 inhibitor to treat advanced solid tumours, biotechnology company One-carbon Therapeutics has announced.  TH9619, a first-in-class, potent, small-molecule, and a dual inhibitor of MTHFD1/2. TH9619 kills cancer cells via a dual mechanism of… Read More

#News

Diffuse large B-cell lymphoma
#Clinical trial #EMA #Follicular lymphoma

EMA issues positive CHMP opinion on Minjuvi 

The European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Minjuvi (tafasitamab) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).  The positive opinion was issued by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The opinion is based on data from… Read More

#News #Regulatory

Patient speaking to psychiatrist
#Clinical trial #Treatment-resistant depression

Positive data announced for treatment-resistant depression drug 

Biopharmaceutical company AtaiBeckley has released positive topline data from the Phase IIb trial of BPL-003 in patients with treatment-resistant depression (TRD).  In the open-label study, BPL-003 met response and remission criteria for depression, with clinically meaningful antidepressant effects sustained up to eight weeks. Patients receiving an 8mg… Read More

#News

#Anti-inflammatory #Clinical trial #Immunology

Apogee Therapeutics announces positive data for I&I antibody 

Biotechnology company Apogee Therapeutics has announced positive Phase I data for its antibody APG333.  APG333, a novel half-life extended TSLP antibody, has been developed for inflammatory and immunology (I&I) markets. In the double-blind, placebo-controlled, first-in-human Phase I clinical trial, APG333 was well tolerated across all cohorts of… Read More

#News

Hepatitis virus
#Bluejay Therapeutics #Clinical trial #hepatitis

Hepatitis D drug achieves 100% virologic response 

Biopharmaceutical company Bluejay Therapeutics’ hepatitis drug candidate has achieved a 100% virologic response at week 48 of clinical trials.  Brelovitug, an investigational, fully human, high-affinity monoclonal antibody (mAb), targets hepatitis B virus surface antigen (anti-HBsAg) in chronic hepatitis D (CHD). The company announced brelovitug achieved 100%… Read More

#News

Cancer research
#Clinical trial #FDA #nda

Relief Therapeutics announces positive results for PKU treatment 

Biopharmaceutical company Relief Therapeutics has announced positive results from its bioequivalence study of RLF-OD032 for the treatment of phenylketonuria (PKU).  The study achieved its primary pharmacokinetic endpoints, demonstrating that RLF-OD032 is bioequivalent to KUVAN Powder, the reference listed drug, as defined by the US Food and Drug Administration… Read More

#News

Laboratory research
#Clinical development #Clinical trial #ischaemic stroke

Lumosa announces positive results from trial of stroke treatment 

Pharmaceutical company Lumosa Therapeutics has announced positive results from its Phase IIb clinical trial of LT3001 in patients with acute ischaemic stroke.  LT3001 met its primary endpoint of safety, with no treatment-related symptomatic intracranial haemorrhage (siCH) observed. The results showed that LT3001 maintained a favourable safety profile… Read More

#News

Child having ultrasound on knee
#Antibody drug conjugate (ADC) #Arthritis #Clinical trial

Lifordi begins human trial of RA treatment after positive results 

Biotechnology company Lifordi Immunotherapeutics has announced its Phase I study of rheumatoid arthritis (RA) treatment LFD-200 is underway, with positive initial results.  LFD-200 is a glucocorticoid antibody-drug conjugate (ADC) that delivers a potent steroid payload directly to immune cells, aiming to maintain the anti-inflammatory benefits of glucocorticoids… Read More

#News

Cancer tumour
#Cancer research #Clinical trial #Domain Therapeutics

First patients dosed in trial of novel tumour treatment

The first patients have been dosed in a Phase I/II trial of Domain Therapeutics’ DT-7012 targeting CCR8 in solid cancer tumours  DT-7012 is a novel immunotherapy candidate designed to selectively deplete intra-tumoural regulatory T cells (Tregs) by targeting CCR8, a receptor predominantly expressed… Read More

#News

#antibiotic #Clinical trial #Financing

smartbax raises €4.7 million to advance antibiotic compound 

Biotechnology company smartbax has announced it has raised €4.7 million to advance a novel antibiotic compound through preclinical stage.  The pre-Series A financing round was led by new investors Anobis Asset and Bayern Kapital, with participation from UnternehmerTUM Funding for Innovators as well as existing investors.  The financing will support… Read More

#Business & Investment #News

Multiple myeloma
#Clinical trial #FDA #Myeloma

FDA grants Fast Track Designation to myeloma treatment HDP-101

The US Food and Drug Administration has granted Fast Track Designation to myeloma candidate HDP-101 from Heidelberg Pharma.  The designation was supported by nonclinical data as well as clinical data from the ongoing Phase I/IIa study with HDP-101, evaluating the safety and antitumour activity of the candidate in patients with… Read More

#News #Regulatory

Osteoarthritis
#Arthritis #Biotech #Clinical trial

Elevara Medicines raises $70 million for RA Phase II trial

Biotechnology company Elevara Medicines has raised $70 million in Series A financing to advance its Phase II rheumatoid arthritis (RA) trial and pipeline.  The Series A proceeds, co-led by Forbion and Sofinnova Partners, will support Elevara’s upcoming Phase II clinical trial of its lead candidate ELV001. The investment will also… Read More

#Business & Investment #News

UK
#Clinical trial #National Institute for Health Research #UK

UK’s NIHR aims to bring commercial research into primary care 

The UK’s National Institute for Health and Care Research (NIHR) has announced plans to establish 14 centres to expand commercial research delivery and improve access to clinical trials.  As revealed in the announcement, NIHR has awarded more than £14 million ($19 million) to GP-led primary care organisations… Read More

#News